Skip to main content

Peer Review reports

From: The efficacy and safety of dalpiciclib, a cyclin-dependent kinase 4/6 inhibitor, in patients with advanced head and neck mucosal melanoma harboring CDK4 amplification

Original Submission
1 Jul 2023 Submitted Original manuscript
16 Jul 2023 Author responded Author comments - Shi Chaoji
Resubmission - Version 2
16 Jul 2023 Submitted Manuscript version 2
25 Aug 2023 Reviewed Reviewer Report
4 Feb 2024 Reviewed Reviewer Report
25 Feb 2024 Author responded Author comments - Shi Chaoji
Resubmission - Version 3
25 Feb 2024 Submitted Manuscript version 3
29 Feb 2024 Reviewed Reviewer Report
10 May 2024 Author responded Author comments - Shi Chaoji
Resubmission - Version 4
10 May 2024 Submitted Manuscript version 4
16 May 2024 Author responded Author comments - Shi Chaoji
Resubmission - Version 5
16 May 2024 Submitted Manuscript version 5
Publishing
20 May 2024 Editorially accepted
29 May 2024 Article published 10.1186/s12916-024-03431-x

You can find further information about peer review here.

Back to article page